Is KNTE undervalued or overvalued?
As of 2025-03-24, the Intrinsic Value of Kinnate Biopharma Inc (KNTE) is -11.94 USD. This KNTE valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.65 USD, the upside of Kinnate Biopharma Inc is -550.59%. This means that KNTE is overvalued by 550.59%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -11.94 - -11.94 | -11.94 | -550.59% |
| P/E | (75.03) - (117.26) | (90.99) | -3533.5% |
| DDM - Stable | (13.02) - (33.48) | (23.25) | -977.4% |
| DDM - Multi | (10.21) - (21.58) | (13.99) | -627.8% |
| Market Cap (mil) | 125.00 |
| Beta | 3.98 |
| Outstanding shares (mil) | 47.17 |
| Enterprise Value (mil) | 68.00 |
| Market risk premium | 4.60% |
| Cost of Equity | 13.63% |
| Cost of Debt | 5.00% |
| WACC | 8.65% |